nodes	percent_of_prediction	percent_of_DWPC	metapath
Gliclazide—VEGFA—uterine cancer	0.606	1	CbGaD
Gliclazide—CYP2C9—Medroxyprogesterone Acetate—uterine cancer	0.0507	0.407	CbGbCtD
Gliclazide—CYP2C19—Progesterone—uterine cancer	0.0404	0.324	CbGbCtD
Gliclazide—CYP2C9—Progesterone—uterine cancer	0.0336	0.269	CbGbCtD
Gliclazide—VEGFA—myometrium—uterine cancer	0.00257	0.103	CbGeAlD
Gliclazide—Glyburide—ABCC9—uterine cancer	0.00247	1	CrCbGaD
Gliclazide—VEGFA—uterine cervix—uterine cancer	0.002	0.08	CbGeAlD
Gliclazide—VEGFA—smooth muscle tissue—uterine cancer	0.00194	0.0778	CbGeAlD
Gliclazide—VEGFA—decidua—uterine cancer	0.0019	0.0763	CbGeAlD
Gliclazide—VEGFA—endometrium—uterine cancer	0.00181	0.0724	CbGeAlD
Gliclazide—VEGFA—mammalian vulva—uterine cancer	0.00175	0.07	CbGeAlD
Gliclazide—VEGFA—uterus—uterine cancer	0.00166	0.0667	CbGeAlD
Gliclazide—VEGFA—female gonad—uterine cancer	0.00136	0.0546	CbGeAlD
Gliclazide—VEGFA—vagina—uterine cancer	0.00135	0.0542	CbGeAlD
Gliclazide—ABCC8—smooth muscle tissue—uterine cancer	0.00128	0.0513	CbGeAlD
Gliclazide—ABCC8—renal system—uterine cancer	0.00123	0.0493	CbGeAlD
Gliclazide—ABCC8—endometrium—uterine cancer	0.00119	0.0477	CbGeAlD
Gliclazide—KCNJ11—female reproductive system—uterine cancer	0.00107	0.0429	CbGeAlD
Gliclazide—KCNJ11—female gonad—uterine cancer	0.000974	0.039	CbGeAlD
Gliclazide—VEGFA—lymph node—uterine cancer	0.000875	0.0351	CbGeAlD
Gliclazide—KCNJ11—lymph node—uterine cancer	0.000626	0.0251	CbGeAlD
Gliclazide—CYP2C19—vagina—uterine cancer	0.000514	0.0206	CbGeAlD
Gliclazide—CYP2C9—female reproductive system—uterine cancer	0.000441	0.0177	CbGeAlD
Gliclazide—ALB—lymph node—uterine cancer	0.000413	0.0166	CbGeAlD
Gliclazide—Increased appetite—Doxorubicin—uterine cancer	0.000131	0.000791	CcSEcCtD
Gliclazide—Rash—Medroxyprogesterone Acetate—uterine cancer	0.00013	0.000787	CcSEcCtD
Gliclazide—Dermatitis—Medroxyprogesterone Acetate—uterine cancer	0.00013	0.000786	CcSEcCtD
Gliclazide—Headache—Medroxyprogesterone Acetate—uterine cancer	0.000129	0.000782	CcSEcCtD
Gliclazide—Renal impairment—Doxorubicin—uterine cancer	0.000129	0.000781	CcSEcCtD
Gliclazide—Malaise—Etoposide—uterine cancer	0.000129	0.000779	CcSEcCtD
Gliclazide—Leukopenia—Etoposide—uterine cancer	0.000128	0.000773	CcSEcCtD
Gliclazide—Body temperature increased—Dactinomycin—uterine cancer	0.000127	0.00077	CcSEcCtD
Gliclazide—Abdominal pain—Dactinomycin—uterine cancer	0.000127	0.00077	CcSEcCtD
Gliclazide—ABCC8—Metabolism—SRD5A2—uterine cancer	0.000126	0.00166	CbGpPWpGaD
Gliclazide—Hypoglycaemia—Doxorubicin—uterine cancer	0.000126	0.000762	CcSEcCtD
Gliclazide—Cardiac failure—Doxorubicin—uterine cancer	0.000126	0.000762	CcSEcCtD
Gliclazide—Loss of consciousness—Etoposide—uterine cancer	0.000125	0.000759	CcSEcCtD
Gliclazide—Cerebrovascular accident—Doxorubicin—uterine cancer	0.000125	0.000759	CcSEcCtD
Gliclazide—Cough—Etoposide—uterine cancer	0.000124	0.000753	CcSEcCtD
Gliclazide—Convulsion—Etoposide—uterine cancer	0.000124	0.000748	CcSEcCtD
Gliclazide—Hyponatraemia—Doxorubicin—uterine cancer	0.000123	0.000747	CcSEcCtD
Gliclazide—Hypertension—Etoposide—uterine cancer	0.000123	0.000745	CcSEcCtD
Gliclazide—Gastrointestinal haemorrhage—Doxorubicin—uterine cancer	0.000123	0.000744	CcSEcCtD
Gliclazide—Osteoarthritis—Doxorubicin—uterine cancer	0.000123	0.000744	CcSEcCtD
Gliclazide—Pain in extremity—Doxorubicin—uterine cancer	0.000123	0.000744	CcSEcCtD
Gliclazide—Diplopia—Doxorubicin—uterine cancer	0.000123	0.000744	CcSEcCtD
Gliclazide—Nausea—Medroxyprogesterone Acetate—uterine cancer	0.000122	0.000741	CcSEcCtD
Gliclazide—ALB—Folate Metabolism—MTHFR—uterine cancer	0.000122	0.00161	CbGpPWpGaD
Gliclazide—KCNJ11—Metabolism—NDUFB11—uterine cancer	0.000122	0.00161	CbGpPWpGaD
Gliclazide—KCNJ11—Metabolism—SRD5A2—uterine cancer	0.000122	0.00161	CbGpPWpGaD
Gliclazide—Dry skin—Epirubicin—uterine cancer	0.000122	0.000737	CcSEcCtD
Gliclazide—Chest pain—Etoposide—uterine cancer	0.000121	0.000735	CcSEcCtD
Gliclazide—Unspecified disorder of skin and subcutaneous tissue—Etoposide—uterine cancer	0.000121	0.00073	CcSEcCtD
Gliclazide—Discomfort—Etoposide—uterine cancer	0.00012	0.000726	CcSEcCtD
Gliclazide—Toxic epidermal necrolysis—Epirubicin—uterine cancer	0.00012	0.000724	CcSEcCtD
Gliclazide—Hypersensitivity—Dactinomycin—uterine cancer	0.000118	0.000717	CcSEcCtD
Gliclazide—ALB—Vitamin B12 Metabolism—CCL2—uterine cancer	0.000118	0.00155	CbGpPWpGaD
Gliclazide—Gastritis—Epirubicin—uterine cancer	0.000117	0.000711	CcSEcCtD
Gliclazide—Confusional state—Etoposide—uterine cancer	0.000117	0.000711	CcSEcCtD
Gliclazide—VEGFA—VEGFA-VEGFR2 Pathway—NRAS—uterine cancer	0.000117	0.00154	CbGpPWpGaD
Gliclazide—CYP2C9—Phase 1 - Functionalization of compounds—CYP19A1—uterine cancer	0.000117	0.00153	CbGpPWpGaD
Gliclazide—Infection—Etoposide—uterine cancer	0.000116	0.0007	CcSEcCtD
Gliclazide—Abdominal distension—Epirubicin—uterine cancer	0.000115	0.000699	CcSEcCtD
Gliclazide—VEGFA—Hemostasis—IRF1—uterine cancer	0.000115	0.00152	CbGpPWpGaD
Gliclazide—Asthenia—Dactinomycin—uterine cancer	0.000115	0.000699	CcSEcCtD
Gliclazide—VEGFA—Integrins in angiogenesis—AKT1—uterine cancer	0.000115	0.00152	CbGpPWpGaD
Gliclazide—Asthma—Epirubicin—uterine cancer	0.000115	0.000695	CcSEcCtD
Gliclazide—Thrombocytopenia—Etoposide—uterine cancer	0.000114	0.00069	CcSEcCtD
Gliclazide—VEGFA—Endochondral Ossification—AKT1—uterine cancer	0.000114	0.0015	CbGpPWpGaD
Gliclazide—Tachycardia—Etoposide—uterine cancer	0.000114	0.000688	CcSEcCtD
Gliclazide—Skin disorder—Etoposide—uterine cancer	0.000113	0.000684	CcSEcCtD
Gliclazide—Dry skin—Doxorubicin—uterine cancer	0.000113	0.000682	CcSEcCtD
Gliclazide—Hyperhidrosis—Etoposide—uterine cancer	0.000113	0.000681	CcSEcCtD
Gliclazide—VEGFA—Oncostatin M Signaling Pathway—AKT1—uterine cancer	0.000112	0.00148	CbGpPWpGaD
Gliclazide—Angina pectoris—Epirubicin—uterine cancer	0.000112	0.000677	CcSEcCtD
Gliclazide—CYP2C19—Metapathway biotransformation—AKR1C1—uterine cancer	0.000112	0.00147	CbGpPWpGaD
Gliclazide—VEGFA—HIF-1-alpha transcription factor network—AKT1—uterine cancer	0.000111	0.00146	CbGpPWpGaD
Gliclazide—Toxic epidermal necrolysis—Doxorubicin—uterine cancer	0.000111	0.00067	CcSEcCtD
Gliclazide—Bronchitis—Epirubicin—uterine cancer	0.00011	0.000668	CcSEcCtD
Gliclazide—VEGFA—Signaling by VEGF—NRAS—uterine cancer	0.00011	0.00145	CbGpPWpGaD
Gliclazide—Diarrhoea—Dactinomycin—uterine cancer	0.00011	0.000666	CcSEcCtD
Gliclazide—Pancytopenia—Epirubicin—uterine cancer	0.000109	0.00066	CcSEcCtD
Gliclazide—Hypotension—Etoposide—uterine cancer	0.000109	0.000658	CcSEcCtD
Gliclazide—Gastritis—Doxorubicin—uterine cancer	0.000109	0.000658	CcSEcCtD
Gliclazide—VEGFA—Signaling events mediated by VEGFR1 and VEGFR2—AKT1—uterine cancer	0.000108	0.00143	CbGpPWpGaD
Gliclazide—VEGFA—SIDS Susceptibility Pathways—CXCL8—uterine cancer	0.000108	0.00142	CbGpPWpGaD
Gliclazide—Abdominal distension—Doxorubicin—uterine cancer	0.000107	0.000647	CcSEcCtD
Gliclazide—Upper respiratory tract infection—Epirubicin—uterine cancer	0.000107	0.000646	CcSEcCtD
Gliclazide—Asthma—Doxorubicin—uterine cancer	0.000106	0.000643	CcSEcCtD
Gliclazide—Photosensitivity reaction—Epirubicin—uterine cancer	0.000105	0.000634	CcSEcCtD
Gliclazide—Paraesthesia—Etoposide—uterine cancer	0.000105	0.000633	CcSEcCtD
Gliclazide—Weight increased—Epirubicin—uterine cancer	0.000104	0.000632	CcSEcCtD
Gliclazide—Dyspnoea—Etoposide—uterine cancer	0.000104	0.000628	CcSEcCtD
Gliclazide—Hyperglycaemia—Epirubicin—uterine cancer	0.000103	0.000627	CcSEcCtD
Gliclazide—Somnolence—Etoposide—uterine cancer	0.000103	0.000626	CcSEcCtD
Gliclazide—Angina pectoris—Doxorubicin—uterine cancer	0.000103	0.000626	CcSEcCtD
Gliclazide—Pneumonia—Epirubicin—uterine cancer	0.000103	0.000623	CcSEcCtD
Gliclazide—Drowsiness—Epirubicin—uterine cancer	0.000102	0.000619	CcSEcCtD
Gliclazide—Vomiting—Dactinomycin—uterine cancer	0.000102	0.000619	CcSEcCtD
Gliclazide—Bronchitis—Doxorubicin—uterine cancer	0.000102	0.000618	CcSEcCtD
Gliclazide—VEGFA—Integrated Breast Cancer Pathway—CTNNB1—uterine cancer	0.000102	0.00134	CbGpPWpGaD
Gliclazide—CYP2C9—Metapathway biotransformation—AKR1C1—uterine cancer	0.000102	0.00134	CbGpPWpGaD
Gliclazide—Stevens-Johnson syndrome—Epirubicin—uterine cancer	0.000101	0.000614	CcSEcCtD
Gliclazide—Rash—Dactinomycin—uterine cancer	0.000101	0.000614	CcSEcCtD
Gliclazide—Pancytopenia—Doxorubicin—uterine cancer	0.000101	0.00061	CcSEcCtD
Gliclazide—VEGFA—VEGFA-VEGFR2 Pathway—KRAS—uterine cancer	0.000101	0.00132	CbGpPWpGaD
Gliclazide—Renal failure—Epirubicin—uterine cancer	0.000101	0.000609	CcSEcCtD
Gliclazide—Gastrointestinal disorder—Etoposide—uterine cancer	0.0001	0.000608	CcSEcCtD
Gliclazide—Fatigue—Etoposide—uterine cancer	0.0001	0.000608	CcSEcCtD
Gliclazide—Neuropathy peripheral—Epirubicin—uterine cancer	0.0001	0.000607	CcSEcCtD
Gliclazide—Jaundice—Epirubicin—uterine cancer	9.97e-05	0.000604	CcSEcCtD
Gliclazide—Pain—Etoposide—uterine cancer	9.95e-05	0.000603	CcSEcCtD
Gliclazide—Constipation—Etoposide—uterine cancer	9.95e-05	0.000603	CcSEcCtD
Gliclazide—Urinary tract infection—Epirubicin—uterine cancer	9.94e-05	0.000602	CcSEcCtD
Gliclazide—Conjunctivitis—Epirubicin—uterine cancer	9.94e-05	0.000602	CcSEcCtD
Gliclazide—VEGFA—Integrated Breast Cancer Pathway—PTEN—uterine cancer	9.94e-05	0.00131	CbGpPWpGaD
Gliclazide—VEGFA—SIDS Susceptibility Pathways—CTNNB1—uterine cancer	9.94e-05	0.00131	CbGpPWpGaD
Gliclazide—Upper respiratory tract infection—Doxorubicin—uterine cancer	9.87e-05	0.000597	CcSEcCtD
Gliclazide—Sweating—Epirubicin—uterine cancer	9.81e-05	0.000594	CcSEcCtD
Gliclazide—CYP2C19—Metapathway biotransformation—GPX3—uterine cancer	9.8e-05	0.00129	CbGpPWpGaD
Gliclazide—ALB—Selenium Micronutrient Network—MTHFR—uterine cancer	9.71e-05	0.00128	CbGpPWpGaD
Gliclazide—VEGFA—Focal Adhesion—ERBB2—uterine cancer	9.7e-05	0.00127	CbGpPWpGaD
Gliclazide—Photosensitivity reaction—Doxorubicin—uterine cancer	9.69e-05	0.000587	CcSEcCtD
Gliclazide—Hepatobiliary disease—Epirubicin—uterine cancer	9.67e-05	0.000586	CcSEcCtD
Gliclazide—Weight increased—Doxorubicin—uterine cancer	9.66e-05	0.000585	CcSEcCtD
Gliclazide—VEGFA—Integrated Pancreatic Cancer Pathway—ERBB2—uterine cancer	9.66e-05	0.00127	CbGpPWpGaD
Gliclazide—Epistaxis—Epirubicin—uterine cancer	9.65e-05	0.000584	CcSEcCtD
Gliclazide—Sinusitis—Epirubicin—uterine cancer	9.6e-05	0.000581	CcSEcCtD
Gliclazide—Feeling abnormal—Etoposide—uterine cancer	9.59e-05	0.000581	CcSEcCtD
Gliclazide—Hyperglycaemia—Doxorubicin—uterine cancer	9.58e-05	0.00058	CcSEcCtD
Gliclazide—ALB—Folate Metabolism—CCL2—uterine cancer	9.57e-05	0.00126	CbGpPWpGaD
Gliclazide—Nausea—Dactinomycin—uterine cancer	9.55e-05	0.000578	CcSEcCtD
Gliclazide—Agranulocytosis—Epirubicin—uterine cancer	9.55e-05	0.000578	CcSEcCtD
Gliclazide—Pneumonia—Doxorubicin—uterine cancer	9.52e-05	0.000576	CcSEcCtD
Gliclazide—Gastrointestinal pain—Etoposide—uterine cancer	9.52e-05	0.000576	CcSEcCtD
Gliclazide—VEGFA—Signaling by VEGF—KRAS—uterine cancer	9.49e-05	0.00125	CbGpPWpGaD
Gliclazide—VEGFA—Integrated Breast Cancer Pathway—EP300—uterine cancer	9.48e-05	0.00125	CbGpPWpGaD
Gliclazide—VEGFA—EPH-Ephrin signaling—HRAS—uterine cancer	9.48e-05	0.00125	CbGpPWpGaD
Gliclazide—Drowsiness—Doxorubicin—uterine cancer	9.46e-05	0.000573	CcSEcCtD
Gliclazide—Stevens-Johnson syndrome—Doxorubicin—uterine cancer	9.38e-05	0.000568	CcSEcCtD
Gliclazide—Bradycardia—Epirubicin—uterine cancer	9.35e-05	0.000566	CcSEcCtD
Gliclazide—Renal failure—Doxorubicin—uterine cancer	9.3e-05	0.000563	CcSEcCtD
Gliclazide—Neuropathy peripheral—Doxorubicin—uterine cancer	9.28e-05	0.000562	CcSEcCtD
Gliclazide—Urticaria—Etoposide—uterine cancer	9.25e-05	0.00056	CcSEcCtD
Gliclazide—VEGFA—VEGFA-VEGFR2 Pathway—PIK3CA—uterine cancer	9.24e-05	0.00121	CbGpPWpGaD
Gliclazide—VEGFA—SIDS Susceptibility Pathways—EP300—uterine cancer	9.24e-05	0.00121	CbGpPWpGaD
Gliclazide—CYP2C19—Biological oxidations—CYP11A1—uterine cancer	9.23e-05	0.00121	CbGpPWpGaD
Gliclazide—Jaundice—Doxorubicin—uterine cancer	9.23e-05	0.000559	CcSEcCtD
Gliclazide—Rhinitis—Epirubicin—uterine cancer	9.21e-05	0.000557	CcSEcCtD
Gliclazide—Body temperature increased—Etoposide—uterine cancer	9.2e-05	0.000557	CcSEcCtD
Gliclazide—Abdominal pain—Etoposide—uterine cancer	9.2e-05	0.000557	CcSEcCtD
Gliclazide—Conjunctivitis—Doxorubicin—uterine cancer	9.2e-05	0.000557	CcSEcCtD
Gliclazide—Urinary tract infection—Doxorubicin—uterine cancer	9.2e-05	0.000557	CcSEcCtD
Gliclazide—Hepatitis—Epirubicin—uterine cancer	9.18e-05	0.000556	CcSEcCtD
Gliclazide—Hypoaesthesia—Epirubicin—uterine cancer	9.14e-05	0.000553	CcSEcCtD
Gliclazide—ALB—Metabolism of lipids and lipoproteins—SRD5A2—uterine cancer	9.12e-05	0.0012	CbGpPWpGaD
Gliclazide—Pharyngitis—Epirubicin—uterine cancer	9.11e-05	0.000552	CcSEcCtD
Gliclazide—ABCC8—Metabolism—AKR1B1—uterine cancer	9.11e-05	0.0012	CbGpPWpGaD
Gliclazide—ABCC8—Metabolism—STAR—uterine cancer	9.11e-05	0.0012	CbGpPWpGaD
Gliclazide—CYP2C19—Metapathway biotransformation—CYP11A1—uterine cancer	9.1e-05	0.0012	CbGpPWpGaD
Gliclazide—Sweating—Doxorubicin—uterine cancer	9.07e-05	0.000549	CcSEcCtD
Gliclazide—Oedema peripheral—Epirubicin—uterine cancer	9.05e-05	0.000548	CcSEcCtD
Gliclazide—Hepatobiliary disease—Doxorubicin—uterine cancer	8.95e-05	0.000542	CcSEcCtD
Gliclazide—VEGFA—Integrated Pancreatic Cancer Pathway—CDKN1B—uterine cancer	8.95e-05	0.00118	CbGpPWpGaD
Gliclazide—CYP2C9—Metapathway biotransformation—GPX3—uterine cancer	8.94e-05	0.00117	CbGpPWpGaD
Gliclazide—Epistaxis—Doxorubicin—uterine cancer	8.93e-05	0.000541	CcSEcCtD
Gliclazide—Sinusitis—Doxorubicin—uterine cancer	8.88e-05	0.000538	CcSEcCtD
Gliclazide—Visual impairment—Epirubicin—uterine cancer	8.85e-05	0.000536	CcSEcCtD
Gliclazide—KCNJ11—Metabolism—STAR—uterine cancer	8.83e-05	0.00116	CbGpPWpGaD
Gliclazide—KCNJ11—Metabolism—AKR1B1—uterine cancer	8.83e-05	0.00116	CbGpPWpGaD
Gliclazide—Agranulocytosis—Doxorubicin—uterine cancer	8.83e-05	0.000535	CcSEcCtD
Gliclazide—VEGFA—Signaling by VEGF—PIK3CA—uterine cancer	8.72e-05	0.00115	CbGpPWpGaD
Gliclazide—Erythema multiforme—Epirubicin—uterine cancer	8.68e-05	0.000526	CcSEcCtD
Gliclazide—VEGFA—Axon guidance—MET—uterine cancer	8.66e-05	0.00114	CbGpPWpGaD
Gliclazide—Bradycardia—Doxorubicin—uterine cancer	8.65e-05	0.000524	CcSEcCtD
Gliclazide—CYP2C19—Metapathway biotransformation—AKR1C3—uterine cancer	8.59e-05	0.00113	CbGpPWpGaD
Gliclazide—Eye disorder—Epirubicin—uterine cancer	8.58e-05	0.00052	CcSEcCtD
Gliclazide—Hypersensitivity—Etoposide—uterine cancer	8.57e-05	0.000519	CcSEcCtD
Gliclazide—Tinnitus—Epirubicin—uterine cancer	8.56e-05	0.000518	CcSEcCtD
Gliclazide—VEGFA—VEGFA-VEGFR2 Pathway—HRAS—uterine cancer	8.55e-05	0.00112	CbGpPWpGaD
Gliclazide—Flushing—Epirubicin—uterine cancer	8.52e-05	0.000516	CcSEcCtD
Gliclazide—Rhinitis—Doxorubicin—uterine cancer	8.52e-05	0.000516	CcSEcCtD
Gliclazide—Hepatitis—Doxorubicin—uterine cancer	8.5e-05	0.000514	CcSEcCtD
Gliclazide—VEGFA—Focal Adhesion—CTNNB1—uterine cancer	8.49e-05	0.00112	CbGpPWpGaD
Gliclazide—Hypoaesthesia—Doxorubicin—uterine cancer	8.45e-05	0.000512	CcSEcCtD
Gliclazide—VEGFA—Integrated Pancreatic Cancer Pathway—CTNNB1—uterine cancer	8.45e-05	0.00111	CbGpPWpGaD
Gliclazide—Pharyngitis—Doxorubicin—uterine cancer	8.43e-05	0.000511	CcSEcCtD
Gliclazide—CYP2C9—Biological oxidations—CYP11A1—uterine cancer	8.41e-05	0.00111	CbGpPWpGaD
Gliclazide—Oedema peripheral—Doxorubicin—uterine cancer	8.37e-05	0.000507	CcSEcCtD
Gliclazide—Asthenia—Etoposide—uterine cancer	8.35e-05	0.000506	CcSEcCtD
Gliclazide—CYP2C9—Metapathway biotransformation—CYP11A1—uterine cancer	8.3e-05	0.00109	CbGpPWpGaD
Gliclazide—VEGFA—Focal Adhesion—PTEN—uterine cancer	8.27e-05	0.00109	CbGpPWpGaD
Gliclazide—Chills—Epirubicin—uterine cancer	8.24e-05	0.000499	CcSEcCtD
Gliclazide—VEGFA—Integrated Pancreatic Cancer Pathway—PTEN—uterine cancer	8.24e-05	0.00108	CbGpPWpGaD
Gliclazide—Pruritus—Etoposide—uterine cancer	8.23e-05	0.000499	CcSEcCtD
Gliclazide—Arrhythmia—Epirubicin—uterine cancer	8.2e-05	0.000497	CcSEcCtD
Gliclazide—CYP2C19—Metabolism of lipids and lipoproteins—SRD5A2—uterine cancer	8.19e-05	0.00108	CbGpPWpGaD
Gliclazide—Visual impairment—Doxorubicin—uterine cancer	8.19e-05	0.000496	CcSEcCtD
Gliclazide—VEGFA—Signaling by VEGF—HRAS—uterine cancer	8.07e-05	0.00106	CbGpPWpGaD
Gliclazide—Mental disorder—Epirubicin—uterine cancer	8.04e-05	0.000487	CcSEcCtD
Gliclazide—Erythema multiforme—Doxorubicin—uterine cancer	8.03e-05	0.000486	CcSEcCtD
Gliclazide—Malnutrition—Epirubicin—uterine cancer	7.99e-05	0.000484	CcSEcCtD
Gliclazide—Erythema—Epirubicin—uterine cancer	7.99e-05	0.000484	CcSEcCtD
Gliclazide—Diarrhoea—Etoposide—uterine cancer	7.96e-05	0.000482	CcSEcCtD
Gliclazide—Eye disorder—Doxorubicin—uterine cancer	7.94e-05	0.000481	CcSEcCtD
Gliclazide—Tinnitus—Doxorubicin—uterine cancer	7.92e-05	0.00048	CcSEcCtD
Gliclazide—Flushing—Doxorubicin—uterine cancer	7.89e-05	0.000477	CcSEcCtD
Gliclazide—Flatulence—Epirubicin—uterine cancer	7.88e-05	0.000477	CcSEcCtD
Gliclazide—VEGFA—Integrated Pancreatic Cancer Pathway—EP300—uterine cancer	7.86e-05	0.00103	CbGpPWpGaD
Gliclazide—Tension—Epirubicin—uterine cancer	7.84e-05	0.000475	CcSEcCtD
Gliclazide—CYP2C9—Metapathway biotransformation—AKR1C3—uterine cancer	7.84e-05	0.00103	CbGpPWpGaD
Gliclazide—VEGFA—Cellular responses to stress—CDKN2A—uterine cancer	7.8e-05	0.00102	CbGpPWpGaD
Gliclazide—Nervousness—Epirubicin—uterine cancer	7.76e-05	0.00047	CcSEcCtD
Gliclazide—Back pain—Epirubicin—uterine cancer	7.73e-05	0.000468	CcSEcCtD
Gliclazide—Dizziness—Etoposide—uterine cancer	7.7e-05	0.000466	CcSEcCtD
Gliclazide—VEGFA—Integrated Breast Cancer Pathway—KRAS—uterine cancer	7.63e-05	0.001	CbGpPWpGaD
Gliclazide—Chills—Doxorubicin—uterine cancer	7.62e-05	0.000462	CcSEcCtD
Gliclazide—ALB—Selenium Micronutrient Network—CCL2—uterine cancer	7.6e-05	0.000999	CbGpPWpGaD
Gliclazide—Arrhythmia—Doxorubicin—uterine cancer	7.59e-05	0.00046	CcSEcCtD
Gliclazide—VEGFA—VEGFA-VEGFR2 Pathway—AKT1—uterine cancer	7.55e-05	0.000992	CbGpPWpGaD
Gliclazide—VEGFA—Developmental Biology—SMAD3—uterine cancer	7.54e-05	0.000991	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—AKR1B10—uterine cancer	7.49e-05	0.000984	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism of lipids and lipoproteins—SRD5A2—uterine cancer	7.47e-05	0.000981	CbGpPWpGaD
Gliclazide—Mental disorder—Doxorubicin—uterine cancer	7.44e-05	0.000451	CcSEcCtD
Gliclazide—Ill-defined disorder—Epirubicin—uterine cancer	7.42e-05	0.000449	CcSEcCtD
Gliclazide—Vomiting—Etoposide—uterine cancer	7.4e-05	0.000448	CcSEcCtD
Gliclazide—Malnutrition—Doxorubicin—uterine cancer	7.4e-05	0.000448	CcSEcCtD
Gliclazide—Erythema—Doxorubicin—uterine cancer	7.4e-05	0.000448	CcSEcCtD
Gliclazide—Anaemia—Epirubicin—uterine cancer	7.39e-05	0.000447	CcSEcCtD
Gliclazide—Agitation—Epirubicin—uterine cancer	7.35e-05	0.000445	CcSEcCtD
Gliclazide—Rash—Etoposide—uterine cancer	7.34e-05	0.000444	CcSEcCtD
Gliclazide—Dermatitis—Etoposide—uterine cancer	7.33e-05	0.000444	CcSEcCtD
Gliclazide—Headache—Etoposide—uterine cancer	7.29e-05	0.000441	CcSEcCtD
Gliclazide—Flatulence—Doxorubicin—uterine cancer	7.29e-05	0.000441	CcSEcCtD
Gliclazide—Tension—Doxorubicin—uterine cancer	7.26e-05	0.000439	CcSEcCtD
Gliclazide—Malaise—Epirubicin—uterine cancer	7.21e-05	0.000436	CcSEcCtD
Gliclazide—Nervousness—Doxorubicin—uterine cancer	7.18e-05	0.000435	CcSEcCtD
Gliclazide—Leukopenia—Epirubicin—uterine cancer	7.15e-05	0.000433	CcSEcCtD
Gliclazide—Back pain—Doxorubicin—uterine cancer	7.15e-05	0.000433	CcSEcCtD
Gliclazide—ABCC8—Metabolism—POLD1—uterine cancer	7.15e-05	0.00094	CbGpPWpGaD
Gliclazide—VEGFA—Signaling by VEGF—AKT1—uterine cancer	7.12e-05	0.000936	CbGpPWpGaD
Gliclazide—VEGFA—Cellular responses to stress—CXCL8—uterine cancer	7.07e-05	0.000929	CbGpPWpGaD
Gliclazide—Palpitations—Epirubicin—uterine cancer	7.06e-05	0.000428	CcSEcCtD
Gliclazide—Loss of consciousness—Epirubicin—uterine cancer	7.03e-05	0.000425	CcSEcCtD
Gliclazide—Cough—Epirubicin—uterine cancer	6.98e-05	0.000422	CcSEcCtD
Gliclazide—KCNJ11—Metabolism—POLD1—uterine cancer	6.93e-05	0.000911	CbGpPWpGaD
Gliclazide—Convulsion—Epirubicin—uterine cancer	6.93e-05	0.000419	CcSEcCtD
Gliclazide—Nausea—Etoposide—uterine cancer	6.91e-05	0.000419	CcSEcCtD
Gliclazide—VEGFA—Cellular responses to stress—CDKN1B—uterine cancer	6.9e-05	0.000907	CbGpPWpGaD
Gliclazide—Hypertension—Epirubicin—uterine cancer	6.9e-05	0.000418	CcSEcCtD
Gliclazide—Ill-defined disorder—Doxorubicin—uterine cancer	6.86e-05	0.000416	CcSEcCtD
Gliclazide—Anaemia—Doxorubicin—uterine cancer	6.84e-05	0.000414	CcSEcCtD
Gliclazide—Myalgia—Epirubicin—uterine cancer	6.81e-05	0.000412	CcSEcCtD
Gliclazide—Chest pain—Epirubicin—uterine cancer	6.81e-05	0.000412	CcSEcCtD
Gliclazide—Arthralgia—Epirubicin—uterine cancer	6.81e-05	0.000412	CcSEcCtD
Gliclazide—Agitation—Doxorubicin—uterine cancer	6.8e-05	0.000412	CcSEcCtD
Gliclazide—CYP2C19—Biological oxidations—CYP19A1—uterine cancer	6.79e-05	0.000892	CbGpPWpGaD
Gliclazide—VEGFA—Integrated Breast Cancer Pathway—TP53—uterine cancer	6.78e-05	0.000892	CbGpPWpGaD
Gliclazide—Anxiety—Epirubicin—uterine cancer	6.78e-05	0.000411	CcSEcCtD
Gliclazide—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—uterine cancer	6.76e-05	0.000409	CcSEcCtD
Gliclazide—Discomfort—Epirubicin—uterine cancer	6.72e-05	0.000407	CcSEcCtD
Gliclazide—CYP2C19—Metapathway biotransformation—CYP19A1—uterine cancer	6.69e-05	0.00088	CbGpPWpGaD
Gliclazide—ABCC8—Metabolism—AKR1C1—uterine cancer	6.69e-05	0.000879	CbGpPWpGaD
Gliclazide—Malaise—Doxorubicin—uterine cancer	6.67e-05	0.000404	CcSEcCtD
Gliclazide—Dry mouth—Epirubicin—uterine cancer	6.66e-05	0.000403	CcSEcCtD
Gliclazide—Leukopenia—Doxorubicin—uterine cancer	6.62e-05	0.000401	CcSEcCtD
Gliclazide—ALB—Metabolism of lipids and lipoproteins—AKR1B1—uterine cancer	6.6e-05	0.000867	CbGpPWpGaD
Gliclazide—ALB—Metabolism of lipids and lipoproteins—STAR—uterine cancer	6.6e-05	0.000867	CbGpPWpGaD
Gliclazide—Confusional state—Epirubicin—uterine cancer	6.58e-05	0.000398	CcSEcCtD
Gliclazide—Palpitations—Doxorubicin—uterine cancer	6.54e-05	0.000396	CcSEcCtD
Gliclazide—Loss of consciousness—Doxorubicin—uterine cancer	6.5e-05	0.000394	CcSEcCtD
Gliclazide—KCNJ11—Metabolism—AKR1C1—uterine cancer	6.48e-05	0.000852	CbGpPWpGaD
Gliclazide—Infection—Epirubicin—uterine cancer	6.48e-05	0.000392	CcSEcCtD
Gliclazide—Cough—Doxorubicin—uterine cancer	6.45e-05	0.000391	CcSEcCtD
Gliclazide—Convulsion—Doxorubicin—uterine cancer	6.41e-05	0.000388	CcSEcCtD
Gliclazide—Nervous system disorder—Epirubicin—uterine cancer	6.4e-05	0.000387	CcSEcCtD
Gliclazide—Thrombocytopenia—Epirubicin—uterine cancer	6.39e-05	0.000387	CcSEcCtD
Gliclazide—Hypertension—Doxorubicin—uterine cancer	6.39e-05	0.000387	CcSEcCtD
Gliclazide—Tachycardia—Epirubicin—uterine cancer	6.37e-05	0.000386	CcSEcCtD
Gliclazide—Skin disorder—Epirubicin—uterine cancer	6.34e-05	0.000384	CcSEcCtD
Gliclazide—VEGFA—Axon guidance—ERBB2—uterine cancer	6.33e-05	0.000832	CbGpPWpGaD
Gliclazide—VEGFA—Integrated Pancreatic Cancer Pathway—KRAS—uterine cancer	6.33e-05	0.000831	CbGpPWpGaD
Gliclazide—Hyperhidrosis—Epirubicin—uterine cancer	6.31e-05	0.000382	CcSEcCtD
Gliclazide—Chest pain—Doxorubicin—uterine cancer	6.3e-05	0.000381	CcSEcCtD
Gliclazide—Arthralgia—Doxorubicin—uterine cancer	6.3e-05	0.000381	CcSEcCtD
Gliclazide—Myalgia—Doxorubicin—uterine cancer	6.3e-05	0.000381	CcSEcCtD
Gliclazide—Anxiety—Doxorubicin—uterine cancer	6.27e-05	0.00038	CcSEcCtD
Gliclazide—ALB—Transmembrane transport of small molecules—ABCC9—uterine cancer	6.27e-05	0.000824	CbGpPWpGaD
Gliclazide—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—uterine cancer	6.25e-05	0.000379	CcSEcCtD
Gliclazide—Discomfort—Doxorubicin—uterine cancer	6.22e-05	0.000377	CcSEcCtD
Gliclazide—VEGFA—Signaling Pathways—RNF43—uterine cancer	6.2e-05	0.000815	CbGpPWpGaD
Gliclazide—CYP2C9—Biological oxidations—CYP19A1—uterine cancer	6.19e-05	0.000813	CbGpPWpGaD
Gliclazide—VEGFA—Developmental Biology—MET—uterine cancer	6.18e-05	0.000812	CbGpPWpGaD
Gliclazide—Dry mouth—Doxorubicin—uterine cancer	6.16e-05	0.000373	CcSEcCtD
Gliclazide—CYP2C9—Metapathway biotransformation—CYP19A1—uterine cancer	6.1e-05	0.000802	CbGpPWpGaD
Gliclazide—Hypotension—Epirubicin—uterine cancer	6.1e-05	0.000369	CcSEcCtD
Gliclazide—Confusional state—Doxorubicin—uterine cancer	6.09e-05	0.000369	CcSEcCtD
Gliclazide—VEGFA—Cellular responses to stress—EP300—uterine cancer	6.06e-05	0.000797	CbGpPWpGaD
Gliclazide—Infection—Doxorubicin—uterine cancer	6e-05	0.000363	CcSEcCtD
Gliclazide—ABCC8—Metabolism—RRM2—uterine cancer	5.96e-05	0.000783	CbGpPWpGaD
Gliclazide—Musculoskeletal discomfort—Epirubicin—uterine cancer	5.94e-05	0.00036	CcSEcCtD
Gliclazide—CYP2C19—Metabolism of lipids and lipoproteins—STAR—uterine cancer	5.92e-05	0.000778	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism of lipids and lipoproteins—AKR1B1—uterine cancer	5.92e-05	0.000778	CbGpPWpGaD
Gliclazide—Nervous system disorder—Doxorubicin—uterine cancer	5.92e-05	0.000358	CcSEcCtD
Gliclazide—Thrombocytopenia—Doxorubicin—uterine cancer	5.91e-05	0.000358	CcSEcCtD
Gliclazide—Insomnia—Epirubicin—uterine cancer	5.9e-05	0.000357	CcSEcCtD
Gliclazide—Tachycardia—Doxorubicin—uterine cancer	5.89e-05	0.000357	CcSEcCtD
Gliclazide—Skin disorder—Doxorubicin—uterine cancer	5.86e-05	0.000355	CcSEcCtD
Gliclazide—Paraesthesia—Epirubicin—uterine cancer	5.86e-05	0.000355	CcSEcCtD
Gliclazide—VEGFA—Focal Adhesion—PIK3CA—uterine cancer	5.84e-05	0.000767	CbGpPWpGaD
Gliclazide—Hyperhidrosis—Doxorubicin—uterine cancer	5.84e-05	0.000353	CcSEcCtD
Gliclazide—Dyspnoea—Epirubicin—uterine cancer	5.82e-05	0.000352	CcSEcCtD
Gliclazide—VEGFA—Integrated Pancreatic Cancer Pathway—PIK3CA—uterine cancer	5.81e-05	0.000764	CbGpPWpGaD
Gliclazide—Somnolence—Epirubicin—uterine cancer	5.8e-05	0.000351	CcSEcCtD
Gliclazide—ABCC8—Metabolism—DCN—uterine cancer	5.79e-05	0.00076	CbGpPWpGaD
Gliclazide—KCNJ11—Metabolism—RRM2—uterine cancer	5.78e-05	0.00076	CbGpPWpGaD
Gliclazide—Dyspepsia—Epirubicin—uterine cancer	5.74e-05	0.000348	CcSEcCtD
Gliclazide—VEGFA—Integrated Breast Cancer Pathway—AKT1—uterine cancer	5.73e-05	0.000753	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—INHBA—uterine cancer	5.67e-05	0.000746	CbGpPWpGaD
Gliclazide—Hypotension—Doxorubicin—uterine cancer	5.64e-05	0.000342	CcSEcCtD
Gliclazide—Gastrointestinal disorder—Epirubicin—uterine cancer	5.63e-05	0.000341	CcSEcCtD
Gliclazide—Fatigue—Epirubicin—uterine cancer	5.62e-05	0.000341	CcSEcCtD
Gliclazide—VEGFA—Integrated Pancreatic Cancer Pathway—TP53—uterine cancer	5.62e-05	0.000739	CbGpPWpGaD
Gliclazide—KCNJ11—Metabolism—DCN—uterine cancer	5.61e-05	0.000737	CbGpPWpGaD
Gliclazide—Pain—Epirubicin—uterine cancer	5.58e-05	0.000338	CcSEcCtD
Gliclazide—Constipation—Epirubicin—uterine cancer	5.58e-05	0.000338	CcSEcCtD
Gliclazide—Musculoskeletal discomfort—Doxorubicin—uterine cancer	5.5e-05	0.000333	CcSEcCtD
Gliclazide—Insomnia—Doxorubicin—uterine cancer	5.46e-05	0.000331	CcSEcCtD
Gliclazide—ABCC8—Metabolism—CYP11A1—uterine cancer	5.45e-05	0.000716	CbGpPWpGaD
Gliclazide—ALB—FOXA2 and FOXA3 transcription factor networks—AKT1—uterine cancer	5.42e-05	0.000713	CbGpPWpGaD
Gliclazide—Paraesthesia—Doxorubicin—uterine cancer	5.42e-05	0.000328	CcSEcCtD
Gliclazide—CYP2C9—Metabolism of lipids and lipoproteins—STAR—uterine cancer	5.4e-05	0.00071	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism of lipids and lipoproteins—AKR1B1—uterine cancer	5.4e-05	0.00071	CbGpPWpGaD
Gliclazide—VEGFA—Focal Adhesion—HRAS—uterine cancer	5.4e-05	0.00071	CbGpPWpGaD
Gliclazide—Dyspnoea—Doxorubicin—uterine cancer	5.38e-05	0.000326	CcSEcCtD
Gliclazide—Feeling abnormal—Epirubicin—uterine cancer	5.38e-05	0.000325	CcSEcCtD
Gliclazide—Somnolence—Doxorubicin—uterine cancer	5.37e-05	0.000325	CcSEcCtD
Gliclazide—Gastrointestinal pain—Epirubicin—uterine cancer	5.33e-05	0.000323	CcSEcCtD
Gliclazide—Dyspepsia—Doxorubicin—uterine cancer	5.31e-05	0.000322	CcSEcCtD
Gliclazide—KCNJ11—Metabolism—CYP11A1—uterine cancer	5.29e-05	0.000695	CbGpPWpGaD
Gliclazide—ALB—Platelet degranulation—VEGFA—uterine cancer	5.27e-05	0.000692	CbGpPWpGaD
Gliclazide—Gastrointestinal disorder—Doxorubicin—uterine cancer	5.21e-05	0.000316	CcSEcCtD
Gliclazide—Fatigue—Doxorubicin—uterine cancer	5.2e-05	0.000315	CcSEcCtD
Gliclazide—Urticaria—Epirubicin—uterine cancer	5.18e-05	0.000314	CcSEcCtD
Gliclazide—VEGFA—Platelet activation, signaling and aggregation—PIK3CA—uterine cancer	5.17e-05	0.00068	CbGpPWpGaD
Gliclazide—Constipation—Doxorubicin—uterine cancer	5.16e-05	0.000313	CcSEcCtD
Gliclazide—Pain—Doxorubicin—uterine cancer	5.16e-05	0.000313	CcSEcCtD
Gliclazide—Abdominal pain—Epirubicin—uterine cancer	5.16e-05	0.000312	CcSEcCtD
Gliclazide—Body temperature increased—Epirubicin—uterine cancer	5.16e-05	0.000312	CcSEcCtD
Gliclazide—ABCC8—Metabolism—AKR1C3—uterine cancer	5.15e-05	0.000677	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—AKR1C1—uterine cancer	5.11e-05	0.000671	CbGpPWpGaD
Gliclazide—ALB—Response to elevated platelet cytosolic Ca2+—VEGFA—uterine cancer	5.02e-05	0.000659	CbGpPWpGaD
Gliclazide—KCNJ11—Metabolism—AKR1C3—uterine cancer	4.99e-05	0.000656	CbGpPWpGaD
Gliclazide—Feeling abnormal—Doxorubicin—uterine cancer	4.97e-05	0.000301	CcSEcCtD
Gliclazide—Gastrointestinal pain—Doxorubicin—uterine cancer	4.94e-05	0.000299	CcSEcCtD
Gliclazide—ALB—Metabolism of lipids and lipoproteins—AKR1C1—uterine cancer	4.84e-05	0.000636	CbGpPWpGaD
Gliclazide—VEGFA—Axon guidance—NRAS—uterine cancer	4.82e-05	0.000633	CbGpPWpGaD
Gliclazide—Hypersensitivity—Epirubicin—uterine cancer	4.81e-05	0.000291	CcSEcCtD
Gliclazide—Urticaria—Doxorubicin—uterine cancer	4.8e-05	0.00029	CcSEcCtD
Gliclazide—Body temperature increased—Doxorubicin—uterine cancer	4.77e-05	0.000289	CcSEcCtD
Gliclazide—Abdominal pain—Doxorubicin—uterine cancer	4.77e-05	0.000289	CcSEcCtD
Gliclazide—VEGFA—Focal Adhesion—AKT1—uterine cancer	4.77e-05	0.000627	CbGpPWpGaD
Gliclazide—VEGFA—Integrated Pancreatic Cancer Pathway—AKT1—uterine cancer	4.75e-05	0.000624	CbGpPWpGaD
Gliclazide—Asthenia—Epirubicin—uterine cancer	4.68e-05	0.000283	CcSEcCtD
Gliclazide—ALB—Folate Metabolism—TP53—uterine cancer	4.64e-05	0.00061	CbGpPWpGaD
Gliclazide—Pruritus—Epirubicin—uterine cancer	4.62e-05	0.000279	CcSEcCtD
Gliclazide—VEGFA—Developmental Biology—ERBB2—uterine cancer	4.52e-05	0.000594	CbGpPWpGaD
Gliclazide—Diarrhoea—Epirubicin—uterine cancer	4.46e-05	0.00027	CcSEcCtD
Gliclazide—Hypersensitivity—Doxorubicin—uterine cancer	4.45e-05	0.000269	CcSEcCtD
Gliclazide—CYP2C19—Metabolism of lipids and lipoproteins—AKR1C1—uterine cancer	4.35e-05	0.000571	CbGpPWpGaD
Gliclazide—ABCC8—Neuronal System—HRAS—uterine cancer	4.35e-05	0.000571	CbGpPWpGaD
Gliclazide—VEGFA—Cellular responses to stress—TP53—uterine cancer	4.34e-05	0.00057	CbGpPWpGaD
Gliclazide—Asthenia—Doxorubicin—uterine cancer	4.33e-05	0.000262	CcSEcCtD
Gliclazide—Dizziness—Epirubicin—uterine cancer	4.31e-05	0.000261	CcSEcCtD
Gliclazide—Pruritus—Doxorubicin—uterine cancer	4.27e-05	0.000259	CcSEcCtD
Gliclazide—VEGFA—Platelet activation, signaling and aggregation—AKT1—uterine cancer	4.22e-05	0.000555	CbGpPWpGaD
Gliclazide—KCNJ11—Neuronal System—HRAS—uterine cancer	4.21e-05	0.000554	CbGpPWpGaD
Gliclazide—Vomiting—Epirubicin—uterine cancer	4.15e-05	0.000251	CcSEcCtD
Gliclazide—VEGFA—Axon guidance—KRAS—uterine cancer	4.14e-05	0.000545	CbGpPWpGaD
Gliclazide—Diarrhoea—Doxorubicin—uterine cancer	4.13e-05	0.00025	CcSEcCtD
Gliclazide—Rash—Epirubicin—uterine cancer	4.11e-05	0.000249	CcSEcCtD
Gliclazide—Dermatitis—Epirubicin—uterine cancer	4.11e-05	0.000249	CcSEcCtD
Gliclazide—Headache—Epirubicin—uterine cancer	4.09e-05	0.000247	CcSEcCtD
Gliclazide—ALB—Hemostasis—IRF1—uterine cancer	4.07e-05	0.000535	CbGpPWpGaD
Gliclazide—ALB—Metabolism—NDUFB11—uterine cancer	4.06e-05	0.000534	CbGpPWpGaD
Gliclazide—ALB—Metabolism—SRD5A2—uterine cancer	4.06e-05	0.000534	CbGpPWpGaD
Gliclazide—ABCC8—Metabolism—STK11—uterine cancer	4.01e-05	0.000527	CbGpPWpGaD
Gliclazide—ABCC8—Metabolism—CYP19A1—uterine cancer	4.01e-05	0.000527	CbGpPWpGaD
Gliclazide—Dizziness—Doxorubicin—uterine cancer	3.99e-05	0.000242	CcSEcCtD
Gliclazide—CYP2C9—Metabolism of lipids and lipoproteins—AKR1C1—uterine cancer	3.96e-05	0.000521	CbGpPWpGaD
Gliclazide—VEGFA—Developmental Biology—CTNNB1—uterine cancer	3.95e-05	0.000519	CbGpPWpGaD
Gliclazide—ALB—Metabolism of lipids and lipoproteins—CYP11A1—uterine cancer	3.95e-05	0.000519	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—AKR1C3—uterine cancer	3.93e-05	0.000517	CbGpPWpGaD
Gliclazide—KCNJ11—Metabolism—CYP19A1—uterine cancer	3.89e-05	0.000511	CbGpPWpGaD
Gliclazide—KCNJ11—Metabolism—STK11—uterine cancer	3.89e-05	0.000511	CbGpPWpGaD
Gliclazide—Nausea—Epirubicin—uterine cancer	3.87e-05	0.000235	CcSEcCtD
Gliclazide—Vomiting—Doxorubicin—uterine cancer	3.84e-05	0.000232	CcSEcCtD
Gliclazide—VEGFA—Signaling Pathways—PGR—uterine cancer	3.83e-05	0.000504	CbGpPWpGaD
Gliclazide—Rash—Doxorubicin—uterine cancer	3.81e-05	0.00023	CcSEcCtD
Gliclazide—Dermatitis—Doxorubicin—uterine cancer	3.8e-05	0.00023	CcSEcCtD
Gliclazide—Headache—Doxorubicin—uterine cancer	3.78e-05	0.000229	CcSEcCtD
Gliclazide—ALB—Metabolism of lipids and lipoproteins—AKR1C3—uterine cancer	3.73e-05	0.00049	CbGpPWpGaD
Gliclazide—VEGFA—Developmental Biology—EP300—uterine cancer	3.67e-05	0.000483	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—YWHAE—uterine cancer	3.66e-05	0.000481	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—NDUFB11—uterine cancer	3.65e-05	0.000479	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—SRD5A2—uterine cancer	3.65e-05	0.000479	CbGpPWpGaD
Gliclazide—VEGFA—Hemostasis—EP300—uterine cancer	3.6e-05	0.000474	CbGpPWpGaD
Gliclazide—Nausea—Doxorubicin—uterine cancer	3.59e-05	0.000217	CcSEcCtD
Gliclazide—CYP2C19—Metabolism of lipids and lipoproteins—CYP11A1—uterine cancer	3.54e-05	0.000466	CbGpPWpGaD
Gliclazide—VEGFA—Axon guidance—HRAS—uterine cancer	3.52e-05	0.000463	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—FBXW7—uterine cancer	3.51e-05	0.000461	CbGpPWpGaD
Gliclazide—VEGFA—Developmental Biology—NRAS—uterine cancer	3.44e-05	0.000452	CbGpPWpGaD
Gliclazide—VEGFA—Hemostasis—NRAS—uterine cancer	3.37e-05	0.000443	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism of lipids and lipoproteins—AKR1C3—uterine cancer	3.35e-05	0.00044	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—SRD5A2—uterine cancer	3.33e-05	0.000437	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—NDUFB11—uterine cancer	3.33e-05	0.000437	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism of lipids and lipoproteins—CYP11A1—uterine cancer	3.23e-05	0.000425	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—STK11—uterine cancer	3.06e-05	0.000403	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism of lipids and lipoproteins—AKR1C3—uterine cancer	3.05e-05	0.000401	CbGpPWpGaD
Gliclazide—ABCC8—Metabolism—MTHFR—uterine cancer	3.01e-05	0.000396	CbGpPWpGaD
Gliclazide—VEGFA—Developmental Biology—KRAS—uterine cancer	2.96e-05	0.000389	CbGpPWpGaD
Gliclazide—ALB—Metabolism—STAR—uterine cancer	2.94e-05	0.000386	CbGpPWpGaD
Gliclazide—ALB—Metabolism—AKR1B1—uterine cancer	2.94e-05	0.000386	CbGpPWpGaD
Gliclazide—KCNJ11—Metabolism—MTHFR—uterine cancer	2.92e-05	0.000384	CbGpPWpGaD
Gliclazide—ALB—Metabolism of lipids and lipoproteins—CYP19A1—uterine cancer	2.9e-05	0.000382	CbGpPWpGaD
Gliclazide—VEGFA—Hemostasis—KRAS—uterine cancer	2.9e-05	0.000381	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—SOCS3—uterine cancer	2.87e-05	0.000377	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—CDKN2B—uterine cancer	2.75e-05	0.000361	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—IGF1R—uterine cancer	2.67e-05	0.000351	CbGpPWpGaD
Gliclazide—VEGFA—Hemostasis—PIK3CA—uterine cancer	2.67e-05	0.00035	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—AKR1B1—uterine cancer	2.64e-05	0.000347	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—STAR—uterine cancer	2.64e-05	0.000347	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism of lipids and lipoproteins—CYP19A1—uterine cancer	2.61e-05	0.000343	CbGpPWpGaD
Gliclazide—VEGFA—Hemostasis—TP53—uterine cancer	2.58e-05	0.000339	CbGpPWpGaD
Gliclazide—VEGFA—Developmental Biology—HRAS—uterine cancer	2.51e-05	0.00033	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—SMAD3—uterine cancer	2.51e-05	0.00033	CbGpPWpGaD
Gliclazide—VEGFA—Hemostasis—HRAS—uterine cancer	2.47e-05	0.000324	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—STAR—uterine cancer	2.4e-05	0.000316	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—AKR1B1—uterine cancer	2.4e-05	0.000316	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—FGFR2—uterine cancer	2.39e-05	0.000314	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism of lipids and lipoproteins—CYP19A1—uterine cancer	2.38e-05	0.000312	CbGpPWpGaD
Gliclazide—ALB—Platelet activation, signaling and aggregation—VEGFA—uterine cancer	2.34e-05	0.000307	CbGpPWpGaD
Gliclazide—ALB—Metabolism—POLD1—uterine cancer	2.31e-05	0.000303	CbGpPWpGaD
Gliclazide—VEGFA—Developmental Biology—AKT1—uterine cancer	2.22e-05	0.000292	CbGpPWpGaD
Gliclazide—VEGFA—Hemostasis—AKT1—uterine cancer	2.18e-05	0.000286	CbGpPWpGaD
Gliclazide—ALB—Metabolism—AKR1C1—uterine cancer	2.16e-05	0.000283	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—POLD1—uterine cancer	2.07e-05	0.000272	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—ESR1—uterine cancer	2.05e-05	0.000269	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—AKR1C1—uterine cancer	1.94e-05	0.000254	CbGpPWpGaD
Gliclazide—ALB—Metabolism—RRM2—uterine cancer	1.92e-05	0.000253	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—POLD1—uterine cancer	1.89e-05	0.000248	CbGpPWpGaD
Gliclazide—ALB—Metabolism—DCN—uterine cancer	1.87e-05	0.000245	CbGpPWpGaD
Gliclazide—ALB—Platelet activation, signaling and aggregation—PIK3CA—uterine cancer	1.82e-05	0.00024	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—CCL2—uterine cancer	1.8e-05	0.000237	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—AKR1C1—uterine cancer	1.76e-05	0.000232	CbGpPWpGaD
Gliclazide—ALB—Metabolism—CYP11A1—uterine cancer	1.76e-05	0.000231	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—RRM2—uterine cancer	1.73e-05	0.000227	CbGpPWpGaD
Gliclazide—ABCC8—Metabolism—PTEN—uterine cancer	1.68e-05	0.00022	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—DCN—uterine cancer	1.67e-05	0.00022	CbGpPWpGaD
Gliclazide—ALB—Metabolism—AKR1C3—uterine cancer	1.66e-05	0.000218	CbGpPWpGaD
Gliclazide—KCNJ11—Metabolism—PTEN—uterine cancer	1.63e-05	0.000214	CbGpPWpGaD
Gliclazide—ABCC8—Metabolism—EP300—uterine cancer	1.6e-05	0.00021	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—CYP11A1—uterine cancer	1.58e-05	0.000207	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—RRM2—uterine cancer	1.57e-05	0.000207	CbGpPWpGaD
Gliclazide—KCNJ11—Metabolism—EP300—uterine cancer	1.55e-05	0.000204	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—DCN—uterine cancer	1.53e-05	0.000201	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—ERBB2—uterine cancer	1.5e-05	0.000197	CbGpPWpGaD
Gliclazide—ALB—Platelet activation, signaling and aggregation—AKT1—uterine cancer	1.49e-05	0.000196	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—AKR1C3—uterine cancer	1.49e-05	0.000196	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—CYP11A1—uterine cancer	1.44e-05	0.000189	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—CXCL8—uterine cancer	1.42e-05	0.000187	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—CDKN1B—uterine cancer	1.39e-05	0.000183	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—AKR1C3—uterine cancer	1.36e-05	0.000179	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—CTNNB1—uterine cancer	1.31e-05	0.000173	CbGpPWpGaD
Gliclazide—ALB—Metabolism—STK11—uterine cancer	1.29e-05	0.00017	CbGpPWpGaD
Gliclazide—ALB—Metabolism—CYP19A1—uterine cancer	1.29e-05	0.00017	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—PTEN—uterine cancer	1.28e-05	0.000168	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—EP300—uterine cancer	1.27e-05	0.000167	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—EP300—uterine cancer	1.22e-05	0.000161	CbGpPWpGaD
Gliclazide—ALB—Metabolism of lipids and lipoproteins—PTEN—uterine cancer	1.21e-05	0.00016	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—VEGFA—uterine cancer	1.2e-05	0.000158	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—NRAS—uterine cancer	1.19e-05	0.000156	CbGpPWpGaD
Gliclazide—ABCC8—Metabolism—PIK3CA—uterine cancer	1.18e-05	0.000155	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—STK11—uterine cancer	1.16e-05	0.000153	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—CYP19A1—uterine cancer	1.16e-05	0.000153	CbGpPWpGaD
Gliclazide—ALB—Metabolism of lipids and lipoproteins—EP300—uterine cancer	1.16e-05	0.000152	CbGpPWpGaD
Gliclazide—KCNJ11—Metabolism—PIK3CA—uterine cancer	1.15e-05	0.000151	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—NRAS—uterine cancer	1.14e-05	0.00015	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism of lipids and lipoproteins—PTEN—uterine cancer	1.09e-05	0.000143	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—STK11—uterine cancer	1.06e-05	0.000139	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—CYP19A1—uterine cancer	1.06e-05	0.000139	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism of lipids and lipoproteins—EP300—uterine cancer	1.04e-05	0.000137	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—KRAS—uterine cancer	1.02e-05	0.000135	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—uterine cancer	9.94e-06	0.000131	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—KRAS—uterine cancer	9.84e-06	0.000129	CbGpPWpGaD
Gliclazide—ALB—Metabolism—MTHFR—uterine cancer	9.72e-06	0.000128	CbGpPWpGaD
Gliclazide—ABCC8—Metabolism—AKT1—uterine cancer	9.66e-06	0.000127	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism of lipids and lipoproteins—EP300—uterine cancer	9.48e-06	0.000125	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—PIK3CA—uterine cancer	9.41e-06	0.000124	CbGpPWpGaD
Gliclazide—KCNJ11—Metabolism—AKT1—uterine cancer	9.37e-06	0.000123	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—TP53—uterine cancer	9.1e-06	0.00012	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—PIK3CA—uterine cancer	9.04e-06	0.000119	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—TP53—uterine cancer	8.74e-06	0.000115	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—MTHFR—uterine cancer	8.72e-06	0.000115	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—HRAS—uterine cancer	8.7e-06	0.000114	CbGpPWpGaD
Gliclazide—ALB—Metabolism of lipids and lipoproteins—PIK3CA—uterine cancer	8.56e-06	0.000113	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—HRAS—uterine cancer	8.36e-06	0.00011	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—MTHFR—uterine cancer	7.95e-06	0.000105	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—uterine cancer	7.69e-06	0.000101	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—AKT1—uterine cancer	7.68e-06	0.000101	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—AKT1—uterine cancer	7.38e-06	9.7e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—uterine cancer	7.01e-06	9.21e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism—PTEN—uterine cancer	5.41e-06	7.1e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism—EP300—uterine cancer	5.16e-06	6.78e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—PTEN—uterine cancer	4.85e-06	6.38e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—EP300—uterine cancer	4.63e-06	6.08e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—PTEN—uterine cancer	4.42e-06	5.82e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—EP300—uterine cancer	4.22e-06	5.55e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism—PIK3CA—uterine cancer	3.81e-06	5.01e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—PIK3CA—uterine cancer	3.42e-06	4.5e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—PIK3CA—uterine cancer	3.12e-06	4.1e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism—AKT1—uterine cancer	3.12e-06	4.09e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—AKT1—uterine cancer	2.8e-06	3.68e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—AKT1—uterine cancer	2.55e-06	3.35e-05	CbGpPWpGaD
